San Diego-dependent Viking Therapeutics marked itself as a significant competitor in the weight loss drug sector in February following revealing promising details from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection and in March the company